Similar articles

• Raising the safety bar--the FDA's coxib meeting.

  Okie S. Okie S. N Engl J Med. 2005 Mar 31;352(13):1283-5. doi: 10.1056/NEJMp058055. N Engl J Med. 2005. PMID: 15800221 No abstract available.
• Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?

  Messerli FH, Sichrovsky T. Messerli FH, et al. Am J Cardiol. 2005 Sep 15;96(6):872-3. doi: 10.1016/j.amjcard.2005.05.038. Am J Cardiol. 2005. PMID: 16169380 Review. No abstract available.
• Drug safety. FDA panel urges caution on many anti-inflammatory drugs.

  Couzin J. Couzin J. Science. 2005 Feb 25;307(5713):1183-5. doi: 10.1126/science.307.5713.1183a. Science. 2005. PMID: 15731414 No abstract available.
• COX-2 inhibitors--a lesson in unexpected problems.

  Drazen JM. Drazen JM. N Engl J Med. 2005 Mar 17;352(11):1131-2. doi: 10.1056/NEJMe058038. Epub 2005 Feb 15. N Engl J Med. 2005. PMID: 15713947 No abstract available.
• COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.

  Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J. Ray WA, et al. Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):67-70. doi: 10.1002/pds.798. Pharmacoepidemiol Drug Saf. 2003. PMID: 12616850 Review. No abstract available.